The Neurotech CRO: Kordata Launches To Power Next-Gen Clinical Trials

A stealth startup called Kordata has launched to revolutionize central nervous system (CNS) clinical trials, combining neurotechnology with enterprise software. Spun out of BIOS, the contract research organization (CRO) aims to address the high failure rate of CNS drug development by integrating digital biomarkers and real-world data collection. Kordata emerges from stealth backed by an undisclosed investment, targeting a $10 billion CNS trial market that has long struggled with subjective endpoints and poor patient retention. The company’s platform leverages neurotech tools—such as wearable EEG, digital cognitive assessments, and passive data streams—to capture objective, continuous data. This approach cuts trial costs and accelerates timelines, potentially transforming how treatments for Alzheimer's, Parkinson's, depression, and other neurological conditions are developed. With CNS trials facing failure rates above 90%, Kordata’s entry signals a growing convergence of neurotechnology and clinical research. The move also reflects broader industry efforts to digitize trial operations and embrace decentralized models. Kordata’s enterprise software layer handles site management, patient engagement, and regulatory compliance, making it a one-stop shop for biotechs and pharma companies. The company is already working with several undisclosed partners on Phase II and III trials. Industry observers note that specialized CROs for neurological conditions are rare, giving Kordata a unique position. The launch comes amid a surge in neurotech investment, with global funding exceeding $8 billion in 2025. Next milestones include expanding its platform to support rare neurological diseases and forging partnerships with academic medical centers. If successful, Kordata could become the template for neurotech-driven drug development.